City Therapeutics (NASDAQ:CTY) Stock Picked Up by Analysts at Stifel Nicolaus

Posted by Brian Himes on Nov 10th, 2026

Equities researchers at Stifel Nicolaus initiated coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $34.00 price target on the stock. Stifel Nicolaus‘s price target would indicate a potential upside of 82.11% from the stock’s current price.

Several other brokerages also recently weighed in on CTY. Wall Street Zen upgraded City Therapeutics to a “hold” rating in a report on Saturday, October 24th. The Goldman Sachs Group began coverage on shares of City Therapeutics in a research report on Tuesday. They set an “early-stage biotech” rating on the stock. Jefferies Financial Group began coverage on shares of City Therapeutics in a research note on Tuesday. They set a “buy” rating and a $32.00 price objective for the company. Finally, Oppenheimer began coverage on shares of City Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $46.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating. According to MarketBeat, City Therapeutics currently has an average rating of “Buy” and an average price target of $37.33.

Read Our Latest Stock Report on City Therapeutics

City Therapeutics Stock Up 2.3%

Shares of NASDAQ:CTY opened at $18.67 on Tuesday. City Therapeutics has a 12-month low of $15.81 and a 12-month high of $23.88.

Insiders Place Their Bets

In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The shares were bought at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the transaction, the insider directly owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This represents a 1.26% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Nelsen acquired 170,000 shares of City Therapeutics stock in a transaction that occurred on Monday, October 19th. The stock was acquired at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the acquisition, the director directly owned 13,692,507 shares in the company, valued at $246,465,126. This represents a 1.26% increase in their position. The disclosure for this purchase is available in the SEC filing.